Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $12.97 billion
- Book Value:
- Revenue TTM:
- $15.60 billion
- Operating Margin TTM:
- Gross Profit TTM:
- $7.03 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Viatris Inc had its IPO on 2020-11-16 under the ticker symbol VTRS.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Viatris Inc has a staff strength of 38,000 employees.
Shares of Viatris Inc opened at $10.04 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $9.78 - $10.13, and closed at $9.87.
This is a -1.4% slip from the previous day's closing price.
A total volume of 15,240,355 shares were traded at the close of the day’s session.
In the last one week, shares of Viatris Inc have slipped by -8.53%.
Viatris Inc's Key Ratios
Viatris Inc has a market cap of $12.97 billion, indicating a price to book ratio of 0.6815 and a price to sales ratio of 0.8076.
In the last 12-months Viatris Inc’s revenue was $15.60 billion with a gross profit of $7.03 billion and an EBITDA of $5.13 billion. The EBITDA ratio measures Viatris Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Viatris Inc’s operating margin was 14.84% while its return on assets stood at 2.9% with a return of equity of 9.12%.
In Q2, Viatris Inc’s quarterly earnings growth was a negative -15% while revenue growth was a negative 4.8%.
Viatris Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $1.53 per share while it has a forward price to earnings multiple of 3.3535 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Viatris Inc’s profitability.
Viatris Inc stock is trading at a EV to sales ratio of 1.9337 and a EV to EBITDA ratio of 6.9693. Its price to sales ratio in the trailing 12-months stood at 0.8076.
Viatris Inc stock pays annual dividends of $0.48 per share, indicating a yield of 4.45% and a payout ratio of 15.69%.
Balance sheet and cash flow metrics
- Total Assets
- $48.70 billion
- Total Liabilities
- $6.52 billion
- Operating Cash Flow
- Capital Expenditure
- $89 million
- Dividend Payout Ratio
Viatris Inc ended 2023 with $48.70 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $48.70 billion while shareholder equity stood at $20.84 billion.
Viatris Inc ended 2023 with $2.41 billion in deferred long-term liabilities, $6.52 billion in other current liabilities, 12200000.00 in common stock, $5.37 billion in retained earnings and $10.53 billion in goodwill. Its cash balance stood at $629.20 million and cash and short-term investments were $629.20 million. The company’s total short-term debt was $1,334,400,000 while long-term debt stood at $17.25 billion.
Viatris Inc’s total current assets stands at $9.78 billion while long-term investments were $154.20 million and short-term investments were $176.80 million. Its net receivables were $3.61 billion compared to accounts payable of $1.31 billion and inventory worth $3.64 billion.
In 2023, Viatris Inc's operating cash flow was $-76600000.00 while its capital expenditure stood at $89 million.
Comparatively, Viatris Inc paid $0.16 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Viatris Inc stock is currently trading at $9.87 per share. It touched a 52-week high of $11.9751 and a 52-week low of $11.9751. Analysts tracking the stock have a 12-month average target price of $14.41.
Its 50-day moving average was $10.5 and 200-day moving average was $10.25 The short ratio stood at 3.61 indicating a short percent outstanding of 0%.
Around 32.5% of the company’s stock are held by insiders while 7819.2% are held by institutions.
Frequently Asked Questions About Viatris Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.